Background: Antibody responses are triggered by binding of antigen to the B-cell antigen receptor (BCR). The strength of the resulting signal determines the outcome of the response, which may vary from the induction of tolerance to the antigen, to the production of specific high-affinity antibodies. Additional cellsurface proteins assist the BCR in its function, and can facilitate or inhibit an antibody response. CD22 is a BCR-associated transmembrane protein, the cytoplasmic tail of which contains three immunoreceptor tyrosine-based inhibitory motifs. These motifs are phosphorylated upon BCR-crosslinking, and can bind the tyrosine phosphatase SHP-1, a putative negative regulator of signalling from the BCR. In order to assess the role of CD22 in vivo, we have generated CD22 -/-mice by targeted gene inactivation.
Background
The B-cell antigen receptor (BCR) on the surface of B lymphocytes is composed of the antigen receptor chains in a complex with the membrane-spanning signal-transducing molecules Ig␣ and Ig␤. Signal transduction from the BCR depends on immunoreceptor tyrosine-based activation motifs (ITAMs) in the cytoplasmic tails of Ig␣ and Ig␤ which are phosphorylated on tyrosine residues after BCR crosslinking [1] . Signal-transducing proteins bind to these phosphorylated tyrosine residues within the ITAMs, become activated and then trigger signalling cascades. Accessory molecules that modulate signalling through the BCR have been identified on the surface of B cells. The CD19/CD21/CD81 complex can positively modulate BCR signalling [2] , whereas CD22 and the Fc␥RIIb receptor have been suggested to be inhibitors of BCR signalling [3] [4] [5] . Accessory molecules can recruit additional signal-transducing proteins to the antigen receptor, using their cytoplasmic tails. In this way, the strength of the signal or the threshold of antigen required for signalling through the antigen receptor can be modulated. Thus, accessory surface proteins can modify the outcome of the B-cell response, which may vary from the induction of antigenic tolerance to the production of highaffinity antibodies.
CD22 is a B-cell specific membrane-bound protein. Upon BCR-crosslinking, CD22 associates with the BCR and is phosphorylated on tyrosine residues within its cytoplasmic tail [6] [7] [8] . The cytoplasmic region of CD22 contains six tyrosine residues, three of which are found within immunoreceptor tyrosine-based inhibitory motif (ITIMs). These recently identified motifs are characterized by the sequence Val/Iso-X-Tyr-X-X-Leu (where X is any amino acid) [9] . The tyrosine phosphatase SHP-1 (also known as PTP1C, HCP or SHPTP1) is a negative regulator of signalling in haematopoietic cells [10] , which can bind to the phosphorylated ITIM of CD22 in vitro and become activated [3] . It was shown in vitro that CD22 can modulate BCR-signalling: when B cells were pretreated with beads coated with anti-CD22, the concentration of antiimmunoglobulin M (IgM) required for the induction of proliferation was two orders of magnitude lower. The interpretation of this result was that the BCR was released from the negative regulation by CD22, mediated by SHP-1 [3] . In similar experiments, the Ca 2+ response associated with B-cell signalling was enhanced following pretreatment of the cells with anti-CD22 [11] . The phosphorylated cytoplasmic tail of CD22 can also bind the Src homology 2 (SH2) domains of Syk and PLC␥, which are important for triggering Ca 2+ influx [12] . Thus, treatment with anti-CD22 may also recruit additional Syk and PLC␥ molecules to the plasma membrane, and, in this way, lower the threshold of signal induction. It has, however, been difficult to obtain direct proof for the proposed mechanism of the negative regulation of BCR signalling by CD22.
Accessory molecules are often involved in cellular adhesion. Lymphocytes can obtain information about their microenvironment upon binding of their cell-surface receptors to ligands expressed on other cells. CD22 has properties of an adhesion molecule and belongs to the sialoadhesin family of receptors. CD22 can bind to ligands carrying ␣2,6 sialic acids expressed at the surface of several cell types in vitro [13] [14] [15] [16] . One ligand for CD22, identified from studies in vitro, is CD45, a transmembrane tyrosine phosphatase expressed on various haematopoietic cells [17] . The adhesion of CD22 to its ligands may be regulated by the activity of the enzyme ␣2,6 sialyltransferase, which generates the ligand for CD22 on target cells; this enzyme may also inhibit adhesion by sialylating CD22 itself on the surface of the B cell [18, 19] .
Recently, mice with a disrupted CD22 gene were described [20] . B cells isolated from these mice showed an increased Ca 2+ flux after BCR-crosslinking. The CD22 targeted mice gave an augmented T-cell dependent response, had an expanded peritoneal B-1 cell population and increased serum titres of autoantibodies [20] . We describe here the generation and phenotype of a CD22 -/-mouse line obtained with a different targeting construct that shows similarities, but also clear differences, to the previously described targeted mouse line. 
Results

Disruption of the CD22 gene
The targeting vector for the CD22 locus was constructed from polymerase chain reaction (PCR) products obtained from C57Bl/6 DNA. The coding sequence of the CD22 gene was disrupted by insertion of a neomycin cassette into exon 11; this exon normally encodes the transmembrane domain of the protein [21] (Fig. 1a) . After transfection of the targeting vector, embryonic stem (ES) cell clones of C57Bl/6 origin [22] that had undergone a proper targeting event were obtained (Fig. 1b) . Subsequently, chimaeric mice were generated that transmitted the mutation into the germline, and the offspring of these chimaeric mice were then bred to homozygosity. Homozygous mutant mice lack surface expression of CD22 as shown by flow-cytometric analysis of CD22-stained splenocytes (Fig. 1c) . Two independent CD22 -/-mouse lines, derived from the ES cell clones 3A and 7F (Fig. 1b) , were generated, which were phenotypically indistinguishable. The lack of surface expression of CD22 on the splenocytes of homozygous mutant mice allowed us to study its expression more precisely in the wild-type mouse. In contrast to other reports [23, 24] , we find that CD22 is expressed as a surface molecule from the pre-B to the mature B-cell stages, with higher levels on more mature B cells (Fig. 2a,c) . Bone marrow cells of RAG2 -/-mice are CD22-negative (data not shown), indicating that CD22 begins to be expressed on the surface of pre-B cells after initiation of rearrangement of the V, D and J segments of the BCR gene locus.
Although CD22 is expressed from an early stage in developing B cells of wild-type mice, B-cell development in CD22 -/-mice was normal. In the bone marrow, pre-B cells (IgM -B220 lo ), immature (IgM lo B220 lo ) and transitional [25] (IgM hi B220 lo-hi ) B cells were found in a normal distribution and in normal numbers (Fig. 3a,b and Table 1 ). However, the population of mature B cells (IgM lo B220 hi or IgD + ) was strongly reduced ( Fig. 3b,d ; also see below). In the peripheral compartment, B cells and T cells were found in normal numbers ( Flow-cytometric analysis of age-and sex-matched CD22 -/-and control mice. Mice were 6 to 10 weeks old. The numbers are means from six mice per group for spleen and bone marrow (two femurs per mouse) or four mice per group for peritoneal cavity and lymph nodes (submandicular, axial, inguinal and para-aortic). (IgM hi IgD lo ) [25] and the overall expression of membranebound mIgM (mIgM) was half the level of that in wildtype mice (Fig. 3e,f) . However, CD22 -/-splenic B cells expressed twice as many major histocompatibility complex (MHC) class II molecules (data not shown), but had normal levels of the pan B-cell marker CD19, of the adhesion molecules CD24, VLA-4 and LFA-1, and of the activation markers CD69, B7.1 and B7.2 (data not shown).
The lymph node was of normal size in CD22 -/-mice (Table 1) , but B cells from these lymph nodes expressed a lower level of mIgM than in wild-type mice (data not shown). In the peritoneal cavity, we found normal numbers of B-1 and B-2 cells (Fig. 3g ,h and Table 1 ). B-1 cells were identified as B220 lo , CD5 + or Mac-1 + , IgD lo and B-2 cells were identified as B220 hi , CD5 -and Mac-1 -, IgD + . In conclusion, most peripheral B cells of CD22 -/-mice were phenotypically similar to mature, resting B cells, but had lower levels of mIgM ( Fig. 3f ) and, paradoxically, enhanced expression of the activation marker MHC class II molecules. CD22 -/-mice had normal serum immunoglobulin levels, except in mice older than 5 months, in which IgM levels were twice that found in control mice (data not shown).
CD22 is a negative regulator of BCR-induced Ca 2+ signalling
The association of CD22 with the BCR and its phosphorylation after BCR-crosslinking suggest that CD22 is involved in signalling from the BCR. We first studied Ca 2+ mobilization. Splenic B cells of CD22 -/-mice showed an increased and prolonged influx of Ca 2+ after stimulation with anti-IgM over a wide range of antibody concentrations, when compared with control B cells (Fig. 4) . Although the average density of mIgM was two-fold lower on CD22 -/-B cells (Fig. 3e,f) , the threshold for the initiation of Ca 2+ flux was at least 10-times lower (Fig. 4) . The response to anti-kappa stimulation, which activates all surface immunoglobulin receptors, was similarly increased (data not shown). The increased Ca 2+ flux found in CD22 -/-B cells is similar to results obtained with SHP-1 -B cells of motheaten mice [26] . As CD22 can bind and activate SHP-1 in vitro [3] , these results suggest that CD22 mediates the negative regulation of the BCR signal through stimulation of the tyrosine phosphatase activity of SHP-1.
Because tyrosine-phosphorylated CD22 can engage and recruit the tyrosine phosphatase SHP-1, as well as the tyrosine kinase Syk [3, 12] , tyrosine phosphorylation of substrates in CD22 -/-B cells was analyzed. The overall pattern and kinetics of tyrosine phosphorylation by anti-kappa stimulation was not greatly changed in CD22 -/-B cells, with exception of the lack of induction of a substrate of 150-160 kDa, which probably corresponds to CD22 [23] (Fig. 5) . Two proteins, which we interpret to be Ig␣ and Ig␤ by their size, were phosphorylated with the same kinetics in CD22 -/-and in normal B cells (Fig. 5) . In immunoprecipitations, we could detect normal tyrosine phosphorylation of Syk in CD22 -/-B cells (data not shown). Thus, CD22 -/-cells are hyperresponsive with respect to Ca 2+ mobilization, but not with respect to general tyrosine phosphorylation.
CD22 -/-B cells show a higher degree of apoptosis after anti-IgM treatment and a hyperproliferative response to LPS
As the strength of Ca 2+ mobilization has been connected with induction of apoptosis [26] , we compared the survival of CD22 -/-and normal B cells after BCR-crosslinking. We first treated CD22 -/-and normal B cells with goat anti-IgM in medium containing foetal calf serum low in mitogenic factors. This treatment resulted in induction of apoptosis, as measured by the appearance of nuclei containing less than diploid (2N) DNA content (Fig. 6a) . More apoptosis was induced in CD22 -/-than in wild-type B cells, particularly at lower anti-IgM concentrations (Fig. 6a) .
We then asked whether CD22 -/-B cells could be rescued from their propensity to apoptosis by other signals. We measured cell numbers and thymidine incorporation after treatment with anti-IgM in the presence of IL-4, with anti-CD40 or with LPS. Treatment with anti-IgM and IL-4, or with anti-CD40 induced a similar proliferation of CD22 -/-and normal B cells (Fig. 6b) . Surprisingly, LPS induced a hyperproliferative response in CD22 -/-B cells (Fig. 6b) . To differentiate whether the hyperproliferative response was B-cell autologous or caused indirectly, for example as a result of a higher sensitivity of CD22 -/-B cells towards macrophage-derived factors, high-density B cells were then purified. The high-density B-cell fraction is depleted of macrophages, which are highly responsive to LPS. High-density B cells showed an increase in proliferation in response to LPS stimulation, as had been observed in the total splenic B-cell fraction (Fig. 6b) , confirming that the higher response to LPS is intrinsic to B cells. In summary, B cells of CD22 -/-mice are more prone to undergo apoptosis after BCR stimulation.
CD22 -/-B cells have a shorter lifespan
If the propensity to undergo apoptosis is mirrored in vivo, we would expect to see either a smaller B-cell compartment or an increased replacement of the dead cells. As the size of the B-cell compartment in CD22 -/-mice is normal (Table 1) , we tested the second possibility and performed labelling experiments with the thymidine analogue BrdU, which is incorporated into the DNA of dividing cells. Mice were treated with BrdU for varying periods of time.
We found that the labelling rate of CD22 -/-splenic B cells was at least 50 % higher than in wild-type mice. Treatment of the mice with BrdU for 24 hours resulted in 8 % BrdU-labelled CD22 -/-and 4 % BrdU-labelled normal splenic B cells; after 3 days of treatment, 21 % of CD22 -/-cells and 15 % of normal B cells were BrdU-labelled. In the lymph nodes, which contain mostly long-lived cells, a 50 % higher labelling of CD22 -/-B cells was also found (data not shown). However, the same proportions of CD22 -/-and normal B cells were in G0/G1 and G2/M phases of the cell cycle (data not shown). As the pool of spleen and lymph node B cells is not increased (Table 1) , we conclude from these data that CD22 -/-B cells have a higher rate of turnover and a shorter average lifespan than wild-type B cells. The dying cells are replaced by recent immigrant B cells from the bone marrow, which are cycling and therefore labelled with BrdU [27] . We have previously shown that transitional B cells are the primary target of negative selection [25] . We therefore interpret the partial loss of this population in CD22 -/-mice (Fig. 3e,f) to be the result of a more extensive negative selection.
Recirculating B cells are almost absent in the bone marrow: CD22 may be involved in homing to this organ
We then asked whether the absence of mature, recirculating cells in the bone marrow was also caused by the shorter lifespan of CD22 -/-B cells. BrdU-labelling experiments confirmed that, in the bone marrow, the pool of long-lived B cells (IgM + BrdU -) was almost absent in CD22 -/-mice (Fig. 7b) . Most bone marrow B cells are labelled within 5 days of BrdU treatment [27] , except for the small population of mature, recirculating B cells (B220 + IgD + ) that were found to be greatly diminished in the CD22 -/-mice (Fig. 3c,d ). Thus, whereas peripheral lymphoid organs had normal levels of B cells in CD22 -/-mice, and a normal number of B cells with a phenotype similar to that of splenic CD22 -/-B cells was found in peripheral blood (data not shown), there was a reduction in the pool of recirculating B cells in the bone marrow. The higher death rate of CD22 -/-cells contributes to the lack of this population in the bone marrow, but it cannot account for the complete loss of this pool.
As CD22 has characteristics of an adhesion molecule [13] [14] [15] [16] , we examined the possibility that the homing of CD22 -/-B cells to the bone marrow was defective. To this end, splenocytes of CD22 -/-and wild-type mice were transferred into RAG2 -/-mice [28] . While the spleens of the recipients were populated equally well by the transferred cells, there was a significantly lower number of CD22 -/-B cells in the bone marrow compared with control B cells (0.13 % versus 0.22 %) (Fig. 8) . These data imply that CD22 is involved either directly or indirectly in homing of recirculating cells to the bone marrow. Although CD22 -/-B cells have an altered phenotype, we did not find evidence for a change in the expression levels of adhesion molecules like CD24, VLA-4 or LFA-1 on the surface of CD22 -/-B cells that could directly explain the alteration in homing behaviour. Therefore, the homing of recirculating B cells could be mediated by a specific interaction between CD22 and a ligand expressed on bone marrow endothelial cells.
T-cell independent responses of CD22 -/-mice are impaired, whereas T-cell dependent responses are normal
To assess the function of the immune system in vivo, we immunized CD22 -/-mice with T-cell dependent and Tcell independent antigens. Both the primary and secondary responses to the T-cell dependent antigen NP-ovalbumin were normal (Fig. 9a) , as was expected from the in vitro stimulation experiments with IL-4 and CD40. Germinal centres with a normal structure were generated (data not shown). Also, the memory response 4 months after the initial priming with antigen was normal (data not shown). These results indicate that CD22 is not required for interactions between B and T cells that generate T-cell dependent immune responses and class switching, as had been proposed following the identification of CD45 as a ligand for CD22 [29] . In contrast, CD22 -/-mice showed significantly impaired responses to the T-cell independent type II antigen TNP-ficoll (Fig.  9b) . The response was three-times lower than in control animals and was seen with three different concentrations of antigen (data not shown). We interpret these data in the 
Bone marrow Spleen
Relative number of IgM + IgD + cells (%)
light of the lowered threshold for stimulation. A T-cell independent antigen that causes a high degree of crosslinking of the BCR may cause deletion rather than stimulation of B cells. By weakening the BCR signal, CD22 may allow an efficient response to bacterial carbohydrate antigens with repetitive structures such as T-cell independent type II antigens. Therefore, CD22 apparently complements the role of CD19, which is important for T-cell dependent, but not T-cell independent immune responses [30] .
Discussion
In a recent paper [20] , a CD22 -/-mouse line was described which showed similarities, but also differences, with the CD22 -/-mouse line described here. The results reported by O'Keefe et al. [20] are in full agreement with ours regarding the phenotype of splenic B cells and as to the functional properties of isolated B cells in vitro. However, analysis in vivo revealed major differences. Our CD22 -/-mice gave normal responses to T-cell dependent antigens, had normal numbers of B-1 cells and, up to the age of 11 months, they showed no signs of autoimmune disease. This contrasts with the CD22 -/-mice reported by O'Keefe et al., which demonstrated higher T-cell dependent antibody responses, an increased number of B-1 cells and production of autoantibodies. Induction of apoptosis, lifespan of B cells and T-cell independent responses were not studied by O'Keefe et al. [20] . The differences in phenotype could well be explained by a residual CD22 expression or by mouse strain differences. Our targeting construct, which deleted parts of exon 11, cannot produce a CD22 molecule with a truncated cytoplasmic tail as aberrant splicing of mRNAs to any of the downstream exons would not preserve the reading frame. Although we cannot formally exclude a residual secretion of a truncated CD22 protein, circumstantial evidence makes this possibility unlikely. The CD22 -/-mouse line described here is on a pure C57Bl/6 background.
The prevailing trait of CD22 -/-mice is the increased and prolonged Ca 2+ -influx after BCR-crosslinking. There is good reason to assume that this change in function is the basis of the phenotype of CD22 -/-mice. CD22 is associated with the BCR and is phosphorylated on tyrosine residues in its cytoplasmic tail after BCR-crosslinking [6] [7] [8] . Three of the tyrosine residues are arranged in ITIMs. These motifs are also found in other surface receptors and exert a negative regulatory function, as has been shown for the Fc␥RIIb receptor expressed on B cells [4, 5] and the killer cell inhibitory receptor (KIR) expressed on NK cells [9] . Co-ligation of the BCR with a Fc␥RIIb receptor carrying a mutation in the ITIM generates a signal that is very similar to that seen in CD22 -/-B cells, and results in no obvious change in the pattern of tyrosine phosphorylation of cellular proteins and an enhanced Ca 2+ flux [5] .
In preliminary experiments, we found that inclusion of the Ca 2+ chelator EGTA in the incubation medium lowered the Ca 2+ flux of CD22 -/-and normal B cells to the same extent, suggesting that Ca 2+ entry from the extracellular space is primarily responsible for the enhanced Ca 2+ mobilization, as was observed in studies of the Fc␥RIIb receptor [5] . In addition, B cells from motheaten mice, deficient 140 Current Biology, Vol 7 No 2
Figure 9
Responses to T-cell dependent and T-cell independent antigens. The response to a T-cell dependent antigen is shown in (a) in terms of NP-specific serum IgG1 levels (arbitrary units) at various days after immunization of wild-type (filled symbols) and CD22 -/-mice (open symbols). Each symbol represents one mouse. The arrows indicate the time points of immunization. The response to the T-cell independent type II antigen TNP-ficoll is shown in (b) in terms of anti-TNP-specific serum IgM levels (arbitrary units) at day 0 and day 5 after immunization of wild-type mice (dark-grey columns) and CD22 -/-mice (light-grey columns). The data shown is the mean and standard deviation of nine mice from each group (p < 0.01 as evaluated by student's t-test). for the tyrosine phosphatase SHP-1, have functional defects similar to those of CD22 -/-B cells [26] . This predicts that SHP-1, or other phosphatases that can bind to ITIMs (for example, the SH2-containing inositol phosphatase SHIP [31] ), mediates the damping effect of CD22 on the Ca 2+ flux. In the case of the Fc␥RIIb receptor, SHIP seems to be more important for the negative regulation of the Ca 2+ influx than SHP-1 [31] . If SHIP can also bind to the ITIMs of CD22, this would explain the higher Ca 2+ influx combined with a relatively unchanged tyrosine-phosphorylation pattern in CD22 -/-B cells.
Increased Ca 2+ fluxes after receptor crosslinking have been correlated with an increased propensity towards apoptosis, and, in SHP-1 -/-mice, to a more effective induction of antigenic tolerance through negative selection [26] . In CD22 -/-mice, an increased induction of apoptosis was also found after BCR-crosslinking in vitro.
Increased apoptosis in vivo would be reflected in the loss of those cells that are most susceptible to negative signals and an enhanced replacement of B cells in the peripheral compartment. Indeed, the population of B cells that we have shown to be most sensitive to tolerance induction, the transitional B cells [25] , is reduced in the spleen of CD22 -/-mice. Moreover, we found a 50 % increased turnover of B cells in the peripheral compartments, reflecting a shorter average lifespan.
The increased sensitivity to apoptosis had no influence on T-cell dependent immune responses, as was expected from the in vitro rescue experiments with IL-4, anti-CD40 or LPS treatment. However, responses to T-cell independent antigens were lower. T-cell independent type II antigens are usually repetitive antigenic determinants on a backbone of varying length that stimulate B cells in the absence of T cells. Negative selection by repetitive antigenic determinants on an indifferent backbone requires a certain hapten density in order to surpass a signalling threshold [32] . We interpret the reduced response to Tcell independent antigens in CD22 -/-mice as reflecting the greater ease with which B cells are negatively selected, because of the increased signal after BCR-crosslinking in the absence of T-cell help. This predicts that immune responses in CD22 -/-mice, in particular to T-cell independent antigens, but most likely also to T-cell dependent antigens, are built up with a different set of immunoglobulin V regions than that in the wild-type mouse.
The shorter lifespan of CD22 -/-B cells could account for the low abundance in CD22 -/-mice of recirculating B cells in the bone marrow, which are normally long-lived. However, we think this cannot account completely for the decrease in the number of these cells seen in vivo and in our repopulation experiments. CD22 has been described as an adhesion molecule [13] [14] [15] 33] and could function as a receptor allowing homing of B cells to the bone marrow.
The fact that normal concentrations of serum proteins can inhibit the adhesive properties of CD22 [34] , makes this model less attractive, but the mechanism could function in particular environments where the concentration of a specific CD22 ligand is high. Finally, we cannot completely exclude the possibility that CD22 -/-B cells may have an altered expression of other adhesion molecules, leading to the recirculation defect.
The phenotypic change of CD22 -/-B cells is not easily explained, but it must be mediated by loss of CD22 and is therefore most likely a reflection of an mIgM-derived signal, which is normally damped by CD22. Reduction of the density of mIgM has been described in anergic B cells [35] . CD22 -/-cells differ functionally from anergic B cells, however, which do not show Ca 2+ fluxes after BCRcrosslinking, respond poorly to LPS and fail to phosphorylate Ig␣ and Ig␤ after BCR-crosslinking [36] . We further found no evidence for a modulation of the expression of B7.1 and B7.2 after culture in vitro, as has been described for anergic B cells [36] . More likely, the phenotype of CD22 -/-B cells is the result of chronic basal stimulation through the BCR. This could explain both the enhanced responsiveness to LPS and the phenotypic changes of the B cells. We are currently testing the hypothesis that lowlevel activation of downstream effectors of the signalling cascades, like the mitogen activated protein kinase cascade, could change the expression level of specific genes.
Materials and methods
Gene targeting
The targeting vector was constructed by PCR amplification of B6 III ES cell DNA using semi-nested PCR. A 2.8 kb fragment from exon 8 to 11 was amplified with the following primers: 5′ GACGTCACCTCCTACA-GATG; 5′ AGAGGATCCATGCCTGTCAGCTGT (both exon 8) and 5′ ACAGTCGACGCAGAAGCCTAGTCCAA (exon 11). A 1.5 kb fragment from exon 11 to exon 15 was amplified with the primers: 5′ ACT-GTCGACTCTTCATCCTGGCCATCT (exon 11) and 5′ GTTGGAGAAGCAGACGTGGC; 5′GGAGGATCCCCAGCCAGA-GAAGGCC ( both exon 15). The primers for exon 11 were tagged with a 5′ SalI restriction site, which was used for inserting the neomycin resistance gene (pMCneoPolyA, Stratagene). ES cell culture and screening was carried out as described [37] , with the exception that clones were transferred onto 96-well plates, trypsinized and split into two samples; one sample was plated on 48-well plates, and the other was lysed on the plates for PCR analysis. For electroporation of ES cells, the targeting vector was linearized with PvuI within the vector backbone.
Flow cytometry and BrdU labelling
Flow cytometric analysis of bone marrow, spleen and peritoneal cavity is representative of at least three independent experiments, which were carried out with groups of two CD22 -/-and two CD22 +/+ littermates of 6-10 weeks of age. Cell suspensions were stained with the following antibodies: Phycoerythrin (PE)-and fluorescein (FITC)-RA3-6B2 (anti-B220), FITC-B7-6 (anti-IgM), PE-goat F(ab′)2 anti-IgM (Caltag), biotin-11-26C (anti-IgD), PE-anti-CD22 (Clone Cy34.1, Pharmingen), FITC-anti-BrdU (Becton Dickinson) and biotin-anti-CD5 (Pharmingen). Biotinylated antibodies were detected with streptavidin-Red670 (Gibco BRL). For BrdU labelling experiments, mice were given 1 mg ml -1 BrdU (Boehringer Mannheim) into the drinking water for 5 days. The anti-BrdU staining was done as described [38] . The BrdU experiment shown is representative of three independent experiments.
Measurement of Ca 2+ influxes
Splenic B cells were loaded with Indo-1 and stained with FITC-antiMac1 and biotin-anti-Thy-1, followed by streptavidin-PE. For flow cytometric analysis of Ca 2+ release, only Mac1-and Thy-1-negative cells (B cells) were analysed. The results are representative for four independent experiments.
Induction of tyrosine phosphorylation
Splenic lymphocytes were depleted of T cells with GK1.5 (anti-CD4), AT83A (anti-Thy1) and 19-178 (anti-CD8), followed by rabbit complement at 37°C for 45 min. The remaining cells were starved for 1 h in medium without FCS at 37°C, stimulated with 10 g ml -1 goat antikappa (Southern Biotechnology Associates) and then lysed [39] . After electrophoresis, the gel was blotted and stained with anti-phosphotyrosine antibody 4G10 (Upstate Biotechnology) and developed with goat anti-mouse IgG-horse radish peroxidase (Southern Biotechnology Associates). The experiment shown is representative of three independent experiments.
Measurement of proliferation
Splenic lymphocytes were prepared and depleted of T cells as described above. B cells were cultured in Iscove's medium at 5 × 10 5 ml -1 (Fig. 4c ) or 1 × 10 6 ml -1 (Fig. 4d) supplemented with 25 g ml -1 B7-6 (anti-IgM) plus 500 U ml -1 IL-4 (Pharmingen); 1 g ml -1 anti-CD40 (Pharmingen) or with 15 g ml -1 LPS EH100 (a generous gift of Dr. Galanos) for 48 h. Proliferation was measured by 3 H thymidine incorporation (2 Ci per well) during the last 6 h of culture (measurements made using an Inotech Trace 96 counter). One part of the experiment was done with percoll-purified fractions of highdensity (hd) or low-density (ld) B cells which were prepared as described [40] . The high-density fraction contained less than 0.5 % Mac-1 hi cells (as judged by flow cytometry). The results are representative of three independent experiments.
Measurement of apoptosis after anti-IgM treatment
Splenocytes of CD22 -/-or normal mice were treated for 24 h with goat anti-IgM in vitro. They were stained with FITC-anti-B220 and fixed in 70 % ethanol at 4°C overnight. The fixed splenocytes were then treated with 10 g ml -1 RNAse at 37°C for 30 min and stained with 25 g ml -1 propidium iodide. The data are representative of two experiments.
Adoptive transfer into RAG2 -/-mice 1 × 10 7 splenocytes of CD22 -/-or normal mice were injected intravenously into RAG2 -/-recipients. After 24 h, the recipient animals were killed, and spleen and bone marrow cells were analyzed by flow cytometry. The experiment shown is representative of two independent experiments.
Immunizations
CD22 -/-mice and normal littermates of 8-12 weeks of age were immunized with TNP-ficoll intraperitoneally (nine mice per group) or with 100 g alum-precipitated NP-ovalbumin together with bordatella pertussis as adjuvant. Enzyme-linked immunosorbant assays were carried out using TNP-BSA or NP-BSA coated plates, respectively, as described [41] . The results shown are each representative of two independent experiments. A second T-cell dependent antigen DNP-ovalbumin was used with similar results.
